April 18th 2024
Adjuvant pembrolizumab had an estimated 91.2% overall survival rate after 4 years compared with 86.0% for patients with clear-cell renal cell carcinoma who received a placebo.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Cabozantinib and Immunotherapy Combination Improves Efficacy in Advanced Renal Cell Cancer Subgroups
February 18th 2023Cabozantinib improved outcomes over placebo for patients with advanced, intermediate-risk renal cell cancer, and showed some efficacy among poor-risk patients in combination with nivolumab and ipilimumab.
Read More
Cabozantinib Therapy Shows Early Efficacy in Advanced RCC After Checkpoint Inhibitor Combonation
February 18th 2023Early data from the phase 2 CaboPoint trial shows a promising response rate among patients with advanced renal cell carcinoma that progressed after checkpoint inhibitor based combination therapy.
Read More
CheckMate-9ER Data Continues to Show Benefit With Nivolumab + Cabozantinib in RCC
February 14th 2023Nivolumab plus cabozantinib led to superior overall survival, progression-free survival, overall response, duration of response, and complete response rates vs sunitinib in patients with advanced renal cell carcinoma.
Read More
Opinions on the Optimal Role of Ipilimumab/Nivolumab in RCC
February 13th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Alan Tan, MD, discussed with participants their experiences with frontline regimens for advanced renal cell carcinoma, and potential trials that could optimize the use of immunotherapy and tyrosine kinase inhibitors. This is the second of 2 articles based on this event.
Read More
Park Discusses Results of Multiple Phase 3 Trials in ccRCC
February 7th 2023During a Targeted Oncology case-based roundtable discussion, Chandler Park, MD, discussed the trials that led to the approval of frontline combination regimens for patients with advanced clear cell renal cell carcinoma.
Read More
Beckermann on Recent Data and Hopes for the Evolving RCC Landscape
February 2nd 2023In an interview with Targeted Oncology, Kathryn Beckermann, MD, PhD, discussed her talk from the International Kidney Cancer Symposium: North America 2022 on risk stratifications and considerations for improving outcomes for patients with renal cell carcinoma.
Read More
Managing Frontline Toxicities in Patients With RCC
February 1st 2023During a Targeted Oncology case-based roundtable event, Moshe Ornstein, MD, MA, discussed with participants their experiences managing toxicities of frontline combination therapy for renal cell carcinoma. This is the second of 2 articles based on this event.
Read More
Physicians Discuss Potential of Frontline Triplet Regimens for RCC
January 27th 2023During a Targeted Oncology case-based roundtable event, Alan Tan, MD, discussed with participants their experience with tyrosine kinase inhibitor/immunotherapy combinations and the most recent results of triplet trials.
Read More
Vaishampayan Reviews Frontline IO/TKI Regimens for Favorable-Risk ccRCC
January 12th 2023During a Targeted Oncology case-based roundtable event, Ulka N. Vaishampayan, MBBS, discussed the frontline combination regimens available for a patient with favorable risk clear cell renal cell carcinoma.
Read More
IO/IO Versus IO/TKI Frontline Therapy for Intermediate-Risk RCC
January 11th 2023During a Targeted Oncology case-based roundtable event, Moshe Ornstein, MD, MA, discussed the factors influencing the choice of frontline therapy for a patient with stage IV clear cell renal cell carcinoma whose risk status was intermediate.
Read More
Second-Line Considerations After Immune Toxicity From Prior RCC Therapy
December 21st 2022During a Targeted Oncology case-based roundtable event, Saby George, MD, discussed which second-line therapy would be appropriate for a patient who discontinued frontline immunotherapy/tyrosine kinase inhibitor therapy due to immune-related toxicity.
Read More
Roundtable Discussion: McKay Covers First-Line Decision-Making for Metastatic RCC
December 20th 2022During a Targeted Oncology case-based roundtable event, Rana McKay, MD, and participants discussed the case of a patient with previously untreated advanced renal cell carcinoma with favorable risk status.
Read More
CheckMate 9ER: Real World and Health-Related Quality of Life Outcomes
December 13th 2022Dr Jonasch shares his perspective on CheckMate 9ER in the real-world setting and discusses the trial’s health-related quality-of-life outcomes data investigating nivolumab plus cabozantinib in advanced renal cell carcinoma treatment.
Watch